The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

After pulling back from IPO attempts in 2022 and 2024, Cambridge-based Insilico Medicine has finally gone public with a ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

Insilico Medicine, an artificial intelligence-driven drug discovery company backed by Qiming Venture Partners, made its debut ...

The biotech, which has a deal with Eli Lilly worth as much as $1.1 billion, is developing two targeted radiopharmaceuticals ...

Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...

The U.S. IPO activity looks sluggish amid the holiday-shortened week. Nevertheless, the week prior saw Texas-based cybersecurity firm SailPoint price its upsized IPO of 60M shares at a public offering ...

The IPO market for new technology listings picked up in 2025. So far this year, at least 23 U.S.-based companies have listed ...

So much for the dog days of summer. During July, 6 more biotech companies took a running leap through the wide-open IPO window, joining a growing pool of newly made ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...